BLAINTRAVENOUSINJECTABLE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
IMULDOSA (ustekinumab-srlf) by Accord Biopharma is igg1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the il-12 and il-23 cytokines. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IMULDOSA (ustekinumab-srlf) is an IgG1κ monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23 cytokines, blocking their pro-inflammatory signaling. It is approved for intravenous use and targets chronic inflammatory conditions where IL-12 and IL-23 drive immune dysregulation. The mechanism disrupts natural killer cell activation and CD4+ T-cell differentiation, reducing the cytokine cascades implicated in inflammatory bowel disease.
Growth
Recent 2024 approval positions IMULDOSA in early growth phase; commercial team investment likely focuses on market penetration and payer contracting in a moderate-competition space.
Mechanism of Action
IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
IMULDOSA offers entry-point or mid-career growth opportunity in a newly approved, IV biologic for serious inflammatory conditions. Early-stage commercialization roles in launch support, payer strategy, and MSL functions will be critical; career impact depends on market uptake and competitive positioning over the next 2-3 years.
Worked on IMULDOSA at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.